KRBP

Kiromic BioPharma, Inc. (KRBP) | Rumor.io

Kiromic BioPharma

KRBP

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about KRBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 19

Kiromic BioPharma's Deltacel-01 clinical trial has shown early efficacy results, with the second patient experiencing primary lung tumor stabilization and complete disappearance of brain metastases.
The company expects to announce initial safety, tolerability, and preliminary efficacy results from the third patient enrolled in Deltacel-01 by the end of March.
Analysts are optimistic about the stock's potential, with some predicting it could reach $30 or even $100.

Generated by AI

Sentiment

Of the messages about KRBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +16.28
Bearish	—	—	—	0% -16.28

Bullish· Jul 28

Kiromic BioPharma's ($KRBP) low float and high volume make it a prime candidate for a short squeeze.
The company's high volume and low market cap suggest that $KRBP is poised to explode in value soon.
$KRBP's low float and high volume indicate that it is a stock to watch for a potential pop in price.

Bearish· May 3

$KRBP has a significant gap to fill before reaching its potential price.
$KRBP is experiencing heavy selling and has lost significant value, with one investor selling 1,000 shares at $4.25.
$KRBP's price is losing steam in low volume, and actual volume could lead to further declines.

Generated by AI

Topics

Of the messages about KRBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	0%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	100%
Analysts	—	—	—	0%

Announcements· May 3

Kiromic BioPharma's IND application has been authorized by the FDA to initiate a Phase 1 clinical trial for Deltacel in non-small cell lung cancer patients.
The company's stock, KRBP, has surged 65% premarket after the FDA announcement.
Trading for KRBP has been resumed on the NASDAQ exchange after a temporary halt.

Controversies· Sep 30

Class action lawsuits have been filed against Kiromic BioPharma, Inc. (KRBP) with lead plaintiff deadlines of October 4, 2022.
Pomerantz Law Firm and Hagens Berman, National Trial Attorneys, are investigating claims on behalf of KRBP investors.
Shareholders of Kiromic BioPharma, Inc. (KRBP) are being encouraged to contact the law firms' attorneys before the October 4th application deadline.

Generated by AI

Community

Of the messages about KRBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	36.54%
Newcomers	—	—	—	63.46%

Also Discussed

Investors talking about KRBP also mention

#	Name	Attention
1	RACY - Relativity Acquisition Corp.	——
2	PBLA - Panbela Therapeutics, Inc.	——
3	Southland Holdings Inc.SLND	0.04%new
4	BTCY - Biotricity, Inc.	——
5	BK Technologies Corporation Common StockBKTI	0%0
6	Marti Technologies Inc.MRT	0%new
7	SBIG - SpringBig Holdings, Inc.	——
8	ICVX - Icosavax, Inc.	——
9	ETAO - ETAO International Co., Ltd.	——
10	PaxMedica Inc.PXMD	0%0